DUSSELDORF, Germany, October 15 /PRNewswire-FirstCall/ --
- Sales in the Third Quarter up by 7.2% to EUR268.0m
- Adjusted Group Results More Than Doubled in the Third Quarter of 2008 From EUR7.4m to EUR16.5m
- Sales Process Started for Technical Plastics Business
- CEO Dr. Axel Herberg Confirms the Outlook for 2008
Gerresheimer AG again achieved a substantial increase in sales and operating results in the third quarter of 2008. Overall, sales by the globally operating manufacturer of special products for the pharma & life science industry totalled EUR268.0m (Q3 2007: EUR250.1m). This is equivalent to growth of 7.2%. On a like-for-like exchange-rate basis sales actually increased by 10.2%. Operating results (Adjusted EBITDA) improved by 14.1% to EUR50.3 m (prior year: EUR44.1m). The adjusted EBITDA margin increased to 18.8% from 17.6%. In the third quarter the sale process for the Technical Plastics business was commenced. This led to non-scheduled depreciation of EUR33.0m, resulting in a negative consolidated result of EUR22.8m for the third quarter. Gerresheimer takes this charge in anticipation of the possible book loss on the sale. The depreciation has no effect on cash flow or operating results. The adjusted net income, which reflects the company's operating profitability, more than doubled in comparison with the prior-year quarter to EUR16.5m (Q3 2007: EUR7.4m). The same applies for adjusted earnings per share, which were substantially higher in the third quarter of 2008 at EUR0.52 (Q3 2007: EUR0.22).
"By focussing on the markets of pharma & life science we have again realised above-average growth this quarter. Gerresheimer is bucking the current negative trend in the global economy and shows that we are a strong company which continues to grow profitably even in difficult times," says Dr. Axel Herberg, Chief Executive Officer of Gerresheimer AG.
The positive result for the third quarter of 2008 is also reflected in the nine-month figures. In the first three quarters of the current financial year Gerresheimer achieved sales of EUR783.4m (Q1-Q3 2007: EUR697.4m). This is equivalent to sales growth of 12.3%. Operating results (Adjusted EBITDA) improved by 18.1% to EUR146.9m (prior year: EUR124.4 m). The Adjusted EBITDA margin was 1.0 percentage point higher than in the first nine months of the prior year and reached 18.8%.
Growth in all divisions
In the third quarter of 2008, sales by the Tubular Glass Division rose by 14.0%, or 19.1% on a like-for-like exchange-rate basis, to EUR77.6 m (prior year: EUR68.1m). The main growth generator in this Division was RTF (Ready-to-Fill) syringe systems, sales of which rose by 54%. Production capacity for RTF syringes is now fully utilised. In order to cover the sustained high level of demand, a substantial investment is being made in this Division and a further production line will be commissioned in early 2009. Growth was also achieved by the Tubular Glass Division in the American market for pharma-ceutical vials and in the Chinese market. Operating results (Adjusted EBITDA) improved by 12.4% to EUR19.1m (Q3 2007: EUR17.0m).
Sales by the Plastic Systems Division increased by 6.2%, or 5.5% on a like-for-like exchange-rate basis, to EUR87.8m (Q3 2007: EUR82.7m). Adjusted EBITDA totalled EUR15.4m, 11.6% up on the prior year (EUR13.8m). A particularly strong contribution to this result was made by the segment of Medical Plastic Systems, with double-digit growth. Integration of the companies acquired at the beginning of 2008 in Spain (today Gerresheimer Zaragoza S.A.) and Brazil (today Gerresheimer Plasticos Sao Paulo Ltda.) has been successfully completed. Both of the companies made a positive contribution to the Division's development. In parallel, the sales process for the segment of Technical Plastic Systems was commenced as part of the company's concentration strategy, under which the Consumer Health Care segment which was also not part of the core business was already sold with effect on June 1, 2008.
The Moulded Glass Division again achieved above-market-average sales growth of 5.0%, or 7.7% on a like-for-like exchange-rate basis, to EUR83.7m (Q3 2007: EUR79.7m). This was attributable in particular to higher sales of pharmaceutical bottles in the USA and Europe. A further growth contributor was cosmetic products. Adjusted EBITDA improved by 14.5% to EUR17.4m (prior year: EUR15.2m).
Sales by the Life Science Research Division increased markedly by 10.1% or 26.4% on a like-for-like exchange-rate basis to EUR22.9m (Q3 2007: EUR20.8m). Adjusted EBITDA of EUR2.9m (Q3 2007: EUR1.8m) even increased by 61.1% compared to prior year.
Growth despite the financial crisis
"Supported by the sustained high level of demand for our products and the stable growth in our core markets of pharma & life science, we confirm our outlook for the current financial year", says Dr. Axel Herberg. Gerresheimer continues to forecast a sales growth of 9% to 11%. In terms of operating results the company expects to achieve an adjusted EBITDA margin of approximately 19.5%.
The company will at the same time continue its successful focus on the markets of pharma & life science. A solid long-term financial structure will allow it to continue to invest in the core markets in the future.
Gerresheimer employs more than 10,000 people in 40 locations in Europe,
America and Asia. In the financial year 2007, worldwide sales totalled
EUR958m. The product portfolio ranges from pharma-ceu-tical vials made of
glass and plastic through to complex drug-delivery systems for the pharma &
life science industry. These include sterile syringes, inhalers and other
system-based approaches for safe dosage and application of medications. The
Group enjoys a leading position in markets which are characterised by high
technical and regulatory barriers.
Group Key Figures (IFRS)
(End of Q3: August 31; Financial Year end November 30)
in EUR million Q3 2008 Q3 2007 Change % Q1-Q3 Q1-Q3 Change % FY 2007
Net sales 268.0 250.1 +7.2 783.4 697.4 +12.3 957.7
Adjusted EBITDA(1) 50.3 44.1 +14.1 146.9 124.4 +18.1 181.6
in % of net sales 18.8 17.6 18.8 17.8 19.0
Adjusted EBITA 32.5 26.6 +22.2 92.9 77.3 +20.2 116.6
in % of net sales 12.1 10.6 11.9 11.1 12.2
operations (EBIT) -10.9 11.0 22.5 34.8 53.3
Net income -22.8 -5.1 -14.7 -13.1 0.8
income(2) 16.5 7.4 >100 44.0 16.4 >100 44.3
Earnings per share
in EUR -0.73 -0.18 -0.53 -0.46 -0.04
per share(3) in EUR 0.52 0.22 >100 1.34 0.48 >100 1.34
Segment Key Figures
in EUR million Q3 2008 Q3 2007 Change % Q1-Q3 Q1-Q3 Change % FY 2007
Net sales 77.6 68.1 +14.0 221.3 199.0 +11.2 271.2
Adjusted EBITDA(1) 19.1 17.0 +12.4 54.2 47.8 +13.4 66.7
Net sales 87.8 82.7 +6.2 258.6 218.6 +18.3 299.7
Adjusted EBITDA(1) 15.4 13.8 +11.6 47.4 38.2 +24.1 56.1
Net sales 83.7 79.7 +5.0 246.9 234.3 +5.4 318.8
Adjusted EBITDA(1) 17.4 15.2 +14.5 52.0 45.2 +15.0 65.1
Net sales 22.9 20.8 +10.1 67.3 47.7 +41.1 72.2
Adjusted EBITDA(1) 2.9 1.8 +61.1 8.0 4.6 +73.9 7.7
(1) Adjusted EBITDA: earnings before income taxes, financial result, amortization of fair value adjustments, extraordinary depreciation, depreciation and amortization, restructuring expenses and one-off income and expenses
(2) Net income before non-cash amortization of fair value adjustments, special effects from restructuring expenses, extraordinary depreciation, the balance of one-off income and expenses (including significant non-cash expenses) and the related tax effects
(3) Adjusted net income after minorities divided by 31.4m shares
You can download the Group's Key Figures at: http://www.presseportal.de/pm/9072/gerresheimer_ag/?keygroup=dokument
Director Corporate PR & Marketing
Contact Investor Relations
Director Corporate Investor Relations
|SOURCE Gerresheimer AG|
Copyright©2008 PR Newswire.
All rights reserved